DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo

Information source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Patients With Active Non-segmental Vitiligo.; Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%; Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo

Intervention: Fluticasone proprionate 0.05% cream (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Overall contact:
Marije Kroon, M.D., Phone: +31205666955, Email: mwkroon@gmail.com


Rationale: Vitiligo vulgaris is a common acquired pigment disorder, which is characterised by the development of depigmented macules. It develops probably due to immunedestruction of melanocytes. Most effective therapies are immunsuppresive: 1. local immunesuppressives like corticosteroids and calcineurin inhibitors 2. phototherapy like PUVA and NB-UVB phototherapy. NB-UVB is the first choice A synergistic effect of UVA and topical corticosteroids (fluticasone proprionate 0. 05% cream) has been described by Westerhof et al. in 1999. To our knowledge to date there are no publications comparing NB-UVB combined with a topical corticosteroid and NB-UVB alone. Objective: The objective of this study is to evaluate the clinical effects (onset and degree of repigmentation) of fluticasone proprionate 0. 05% cream (thrice weekly) on NB-UVB phototherapy twice weekly for a period of 12 months. Study design: Prospective single blinded randomised controlled study. Study population: Consecutive patients ≥ 18 years, diagnosed with active vitiligo vulgaris who will receive NB-UVB phototherapeutic treatment at the Netherlands Institute for Pigment Disorders at the Academic Medical Centre (AMC), University of Amsterdam. Methods: The patient will be randomised for either NB-UVB phototherapy and fluticasone proprionate 0. 05% cream or NB-UVB phototherapy alone for 12 consecutive months. Main study parameters/endpoints: The onset and degree of repigmentation is assessed by digital image analysis of a target lesion and blinded global physician assessment. Furthermore, the patients and doctors satisfaction will be assessed and changes of immunohistochemical parameters will be analysed in skin biopsies. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects participating in the study will be asked to visit the institute 4 times. The time investment will be 20 minutes per visit. Additionally, patients will be asked for consent to take punch biopsies (3 mm) at the beginning and at the end of the treatment period. Hence, skin biopsies are not compulsory for participation in this study. Patients may chose to participate in the clinical non invasive part of the study. Known side effects of the NB-UVB phototherapy are redness, pruritus, xerosis cutis, burning sensation and conjunctivitis. These side-effects however, are largely dose-dependent and avoidable. Corticosteroid associated systemic side-effects (suppression of the adrenocortex) will be minimized by treating only a limited body surface [a maximum of 30% body surface] and by using an intermittent application scheme of three days a week in the long term treatment. The regions which are known to have a higher absorption are excluded (periorbital, axillary, inguinal and genital area). Both topical corticosteroids and NB-UVB are part of the Dutch and British guidelines for the treatment of vitiligo. There is no presumptive evidence or indication that the combination of these therapies may result in a higher risk of side effects. All together the burden due to the study is low and the risk for systemic or local side effects is low.

Clinical Details

Official title: Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Repigmentation of the vitiligo lesions

Secondary outcome: Patients satisfaction


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- non-segmental vitiligo

- Eligible for NB-UVB therapy

- Subjects attending the outpatient department of the SNIP

- patients > 18 years

- Skin type II-V

- patients with active vitiligo: progression of older lesions or development of new

lesion during the last 6 months

- Subject is willing and able to give written informed consent

Exclusion Criteria:

- Personal or a family history of skin cancer ( non-melanoma skincancer: first degree

family members, melanoma: any family members)

- Personal history of photosensitivity and/or phototoxicity disorders

- pregnancy

- Taking medication known to cause photosensitivity, phototoxicity, immune suppression

and chronic or very frequent use of any medication that can influence the UVB response (e. g. tetracycline, retinoids, sulfonamids, psoralens)

- Other skin diseases that would impair the evaluation of repigmentation

- not able to have 2 times weekly NB-UVB phototherapy

- With local immunosuppressive treatment or 6 weeks prior to enrolment. For these

patients a washout period of 6 weeks will be required.

- Contact-allergy for any of the parts in fluticasone proprionate

Locations and Contacts

Marije Kroon, M.D., Phone: +31205666955, Email: mwkroon@gmail.com

Netherlands Institute for Pigments Disorders, Amsterdam 1105AZ, Netherlands; Recruiting
Albert Wolkerstorfer, M.D. PhD, Principal Investigator
Additional Information

Starting date: September 2009
Last updated: November 23, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017